ARWR
Arrowhead Pharmaceuticals, Inc. NASDAQ$74.81
After hrs
$76.39
+0.00%
Mkt Cap $10.0B
52w Low $12.44
97.0% of range
52w High $76.76
50d MA $63.34
200d MA $48.02
P/E (TTM)
-6132.0x
EV/EBITDA
28.8x
P/B
19.9x
Debt/Equity
0.8x
ROE
35.6%
P/FCF
29.4x
RSI (14)
—
ATR (14)
—
Beta
1.27
50d MA
$63.34
200d MA
$48.02
Avg Volume
2.7M
About
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 5, 2026 | AMC | 0.60 | 0.22 | -63.3% | 64.64 | +1.3% | -0.2% | -3.1% | -2.7% | -4.8% | -3.5% | -6.1% | — |
| Nov 25, 2025 | AMC | -0.11 | -0.18 | -61.3% | 46.79 | +1.3% | +23.3% | +12.6% | +20.2% | +23.9% | +39.1% | +49.9% | — |
| Aug 7, 2025 | AMC | -0.94 | -1.26 | -34.0% | 16.06 | -3.2% | +2.2% | +7.2% | +10.8% | +24.5% | +16.9% | +69.2% | — |
| May 12, 2025 | AMC | -0.06 | 2.75 | +4683.3% | 13.97 | +12.7% | +9.4% | +6.7% | +9.8% | +12.5% | +12.7% | +19.8% | — |
| Feb 10, 2025 | AMC | -0.42 | -1.39 | -231.0% | 19.92 | -8.5% | -5.2% | -6.8% | -4.1% | +0.2% | +2.6% | -20.8% | — |
| Nov 26, 2024 | AMC | -1.05 | -1.38 | -31.4% | 21.05 | +6.3% | +24.2% | +23.7% | +25.1% | +23.8% | +9.8% | -7.2% | — |
| Aug 8, 2024 | AMC | -0.58 | -1.38 | -137.9% | 25.85 | -3.3% | -9.4% | -11.3% | -11.6% | -12.2% | -12.3% | -15.8% | — |
| May 9, 2024 | AMC | -0.06 | -1.02 | -1600.0% | 24.72 | +3.1% | -10.7% | -10.8% | -7.3% | +1.3% | +1.1% | -0.8% | — |
| Feb 6, 2024 | AMC | -0.78 | -1.24 | -59.0% | 33.20 | -4.4% | -4.7% | -7.1% | -1.9% | -2.8% | -9.9% | +0.0% | — |
| Nov 29, 2023 | AMC | -0.70 | -1.03 | -47.1% | 28.98 | -3.0% | -26.8% | -20.0% | -14.0% | -19.2% | -17.9% | +5.6% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | JP Morgan | Initiates | Overweight | $88 | $73.48 | $74.56 | +1.5% | +1.8% | — | — | — | — |
| Apr 21 | Morgan Stanley | Upgrade | Equal-Weight → Overweight | $100 | $69.25 | $71.93 | +3.9% | +2.6% | +6.7% | +7.4% | +6.7% | +6.3% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $56.27 | $57.29 | +1.8% | +8.0% | +8.0% | +2.7% | +2.5% | +11.4% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $62.64 | $62.68 | +0.1% | +0.4% | -1.7% | -0.4% | +1.9% | +1.7% |
| Jan 22 | B. Riley Securities | Maintains | Buy → Buy | — | $67.60 | $68.95 | +2.0% | +2.9% | -0.8% | -1.2% | -1.0% | -3.0% |
| Jan 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $65.28 | $65.76 | +0.7% | +3.6% | +6.6% | +2.7% | +2.4% | +2.5% |
| Jan 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $65.93 | $66.10 | +0.3% | -0.6% | -0.0% | +0.5% | -3.2% | -1.0% |
| Jan 7 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $70.81 | $66.13 | -6.6% | -7.2% | -8.2% | -8.8% | -6.9% | -7.4% |
| Jan 7 | Chardan Capital | Maintains | Buy → Buy | — | $70.81 | $66.13 | -6.6% | -7.2% | -8.2% | -8.8% | -6.9% | -7.4% |
| Jan 7 | Goldman Sachs | Maintains | Neutral → Neutral | — | $70.81 | $66.13 | -6.6% | -7.2% | -8.2% | -8.8% | -6.9% | -7.4% |
Recent Filings
8-K
Unknown — 8-K Filing
This is a routine SEC filing document cover page with standard corporate identification information; it contains no material business updates that would impact ARWR's stock valuation or investor decisions.
Mar 20
8-K
Arrowhead Research Corporation -- 8-K Filing
Arrowhead Pharmaceuticals reported Q1 fiscal 2026 results and is hosting a conference call today, providing investors with updates on financial performance and pipeline progress.
Feb 5
Data updated apr 24, 2026 7:06pm
· Source: massive.com